Literature DB >> 12761670

Genetic and metabolic determinants of increased plasma plasminogen activator inhibitor-1 activity in children with renal transplants.

Luis Aldámiz-Echevarría1, Pablo Sanjurjo, Alfredo Vallo, Mireia Aguirre, Gustavo Pérez-Nanclares, Pilar Gimeno, Miguel Rueda, José Ignacio Ruiz, Juan Rodríguez-Soriano.   

Abstract

Recent studies have shown that activity of plasminogen activator inhibitor-1 (PAI-1), a prothrombotic protein, may be increased in transplanted patients. The aim of the present investigation was to determine PAI-1 activity in pediatric recipients of renal transplants and to establish the relative contribution of both genetic and metabolic factors. In 29 children and adolescents with stable renal transplants, we related plasma PAI-1 activity to an indicator of inflammatory status [plasma concentration of C-reactive protein (CRP)] and to elements of the insulin resistance syndrome [body mass index (BMI), fasting insulinemia, HOMA index and plasma triglyceride, HDL-cholesterol, apolipoproteins A-1 and B concentrations]. Polymorphisms of PAI-1, apolipoprotein E (apoE) and angiotensin-converting enzyme (ACE) genes were also investigated. In all patients the study was repeated 1 year later. PAI-1 activity remained constantly elevated (23.4+/-22.8 and 18.6+/-7.8 U/ml in the first and second study, respectively, P=NS). Plasma PAI-1 activity correlated positively with CRP ( P=0.001), BMI z score ( P=0.02), fasting insulinemia ( P=0.009), and HOMA index ( P=0.006). No significant correlations were found in this population between plasma PAI-1 activity and age, gender, time elapsed after transplantation and plasma homocysteine, total cholesterol, LDL-cholesterol, HDL-cholesterol, apolipoprotein B, and apolipoprotein A-1. Plasma PAI-1 activity was not related to the cumulative dose of prednisone, cyclosporin A, or tacrolimus. Plasma PAI-1 activity was significantly higher in 5 children with apoE3/apoE4 genotype. No apparent influences of the PAI-1 4G/4G and ACE I/D genotypes were observed. In a multiple stepwise regression model, fasting insulinemia and apoE3/apoE4 genotype accounted for 45% of the observed plasma PAI-1 variability. We conclude that increased PAI-1 activity in children with stable renal transplants is determined both by genetic factors and by metabolic factors, the latter mainly linked to the insulin resistance syndrome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761670     DOI: 10.1007/s00467-003-1157-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  45 in total

1.  PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction.

Authors:  T Oda; Y O Jung; H S Kim; X Cai; J M López-Guisa; Y Ikeda; A A Eddy
Journal:  Kidney Int       Date:  2001-08       Impact factor: 10.612

2.  Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy.

Authors:  J Hjelmesaeth; K Midtvedt; T Jenssen; A Hartmann
Journal:  Diabetes Care       Date:  2001-12       Impact factor: 19.112

Review 3.  Plasminogen activator inhibitor 1 and atherothrombosis.

Authors:  I Juhan-Vague; M C Alessi
Journal:  Thromb Haemost       Date:  1993-07-01       Impact factor: 5.249

Review 4.  Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis.

Authors:  T K Nordt; J Lohrmann; C Bode
Journal:  Thromb Res       Date:  2001-09-30       Impact factor: 3.944

5.  Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat.

Authors:  A Szabo; J Lutz; K Schleimer; B Antus; P Hamar; T Philipp; U Heemann
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

6.  High cysteine levels in renal transplant recipients: relationship with hyperhomocysteinemia and 5,10-MTHFR polymorphism.

Authors:  R Marcucci; S Fedi; T Brunelli; G Pepe; D Prisco; A Rosati; M Zanazzi; E Bertoni; R Abbate; M Salvadori
Journal:  Transplantation       Date:  2001-03-27       Impact factor: 4.939

7.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

Authors:  A M Thögersen; J H Jansson; K Boman; T K Nilsson; L Weinehall; F Huhtasaari; G Hallmans
Journal:  Circulation       Date:  1998-11-24       Impact factor: 29.690

8.  The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde.

Authors:  S Ye; F R Green; P Y Scarabin; V Nicaud; L Bara; S J Dawson; S E Humphries; A Evans; G Luc; J P Cambou
Journal:  Thromb Haemost       Date:  1995-09       Impact factor: 5.249

9.  Hyperhomocysteinemia in children with renal transplants.

Authors:  Luis Aldámiz-Echevarría; Pablo Sanjurjo; Alfredo Vallo; Lourdes Aquino; Gustavo Pérez-Nanclares; Pilar Gimeno; Miguel Rueda; Ignacio Ruiz; Roser Urreizti; Juan Rodríguez-Soriano
Journal:  Pediatr Nephrol       Date:  2002-06-11       Impact factor: 3.714

10.  Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment.

Authors:  G M Patrassi; M T Sartori; P Rigotti; D Di Landro; P Theodoridis; M Fioretti; M Capalbo; G Saggiorato; G Boeri; A Girolami
Journal:  Transplantation       Date:  1995-05-27       Impact factor: 4.939

View more
  3 in total

1.  A study on glucose metabolism in a small cohort of children and adolescents with kidney transplant.

Authors:  M Giordano; V Colella; A Dammacco; C Torelli; G Grandaliano; A Teutonico; T Depalo; D A Caringella; S Di Paolo
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 4.256

2.  Influence of diet on atherogenic risk in children with renal transplants.

Authors:  Luis Aldámiz-Echevarría; Alfredo Vallo; Pablo Sanjurjo; Javier Elorz; José Angel Prieto; José Ignacio Ruiz; Juan Rodríguez-Soriano
Journal:  Pediatr Nephrol       Date:  2004-07-16       Impact factor: 3.714

3.  Apolipoprotein polymorphism is associated with pro-thrombotic profile in non-demented dyslipidemic subjects.

Authors:  Cláudia N Ferreira; Maria G Carvalho; Karina B Gomes; Helton J Reis; Ana-Paula Fernandes; András Palotás; Marinez O Sousa
Journal:  Exp Biol Med (Maywood)       Date:  2014-07-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.